Literature DB >> 3938828

Increased nephrotoxicity of gentamicin in pyelonephritic rats.

D Beauchamp, A Poirier, M G Bergeron.   

Abstract

Multiple factors may increase the nephrotoxic potential of aminoglycosides. We studied gentamicin susceptibility of kidneys infected with E. coli. Several parameters of renal function, histological changes on light and electron microscopy, and drug levels in renal parenchyma were compared in pyelonephritic and normal rats treated with low doses (10 mg/kg/Q8 hr for 3 days), or high doses (60 mg/kg/day for 14 days), of gentamicin. A significant increase (P less than 0.01) in beta-galactosidase and protein excreted in urine over a period of 17 days associated with severe changes in diuresis and osmolality was noted in the infected treated rats (low doses) compared with normal, treated, infected or control animals. Histological modifications compatible with gentamicin nephrotoxicity were more persistent in the infected treated animals. A significant decrease in 14C inulin (P less than 0.01) and 3H-PAH clearance and secretion (P less than 0.02) was observed in the infected treated rats receiving high doses of antibiotics. Cellular necrosis and tubular desquamation also were more severe in this group. Gentamicin levels in the cortex and medulla of infected animals were significantly higher than in the normals (P less than 0.01) and might have been responsible for the increased toxicity noted in the pyelonephritic animals. Infected kidneys appeared to be more susceptible to the nephrotoxic potential of gentamicin.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3938828     DOI: 10.1038/ki.1985.128

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  15 in total

1.  Pharmacologic Basis for the Treatment of Pyelonephritis.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  1999-10       Impact factor: 3.725

2.  Influence of hydrocortisone on gentamicin-induced nephrotoxicity in rats.

Authors:  D Beauchamp; M Pettigrew
Journal:  Antimicrob Agents Chemother       Date:  1988-07       Impact factor: 5.191

Review 3.  Significance of tissue levels for prediction of antibiotic efficacy and determination of dosage.

Authors:  C Carbon
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-07       Impact factor: 3.267

4.  Increased renal uptake of gentamicin in endotoxemic rats receiving concomitant thromboxane A2 antagonist therapy.

Authors:  M Tardif; Y Bergeron; D Beauchamp; M G Bergeron
Journal:  Antimicrob Agents Chemother       Date:  1993-12       Impact factor: 5.191

5.  Influence of endotoxin on the intrarenal distribution of gentamicin, netilmicin, tobramycin, amikacin, and cephalothin.

Authors:  M G Bergeron; Y Bergeron
Journal:  Antimicrob Agents Chemother       Date:  1986-01       Impact factor: 5.191

6.  Autoradiography of tobramycin uptake by the proximal and distal tubules of normal and endotoxin-treated rats.

Authors:  M G Bergeron; Y Bergeron; Y Marois
Journal:  Antimicrob Agents Chemother       Date:  1986-06       Impact factor: 5.191

Review 7.  A guideline for the inpatient care of children with pyelonephritis.

Authors:  Aftab S Chishti; Erich C Maul; Rubén J Nazario; Jeffrey S Bennett; Stefan G Kiessling
Journal:  Ann Saudi Med       Date:  2010 Sep-Oct       Impact factor: 1.526

8.  Prolonged endotoxemia enhances the renal injuries induced by gentamicin in rats.

Authors:  P Auclair; D Tardif; D Beauchamp; P Gourde; M G Bergeron
Journal:  Antimicrob Agents Chemother       Date:  1990-05       Impact factor: 5.191

9.  L-651,392, a potent leukotriene inhibitor, controls inflammatory process in Escherichia coli pyelonephritis.

Authors:  M Tardif; D Beauchamp; Y Bergeron; C Lessard; P Gourde; M G Bergeron
Journal:  Antimicrob Agents Chemother       Date:  1994-07       Impact factor: 5.191

10.  Renal pharmacokinetic changes of gentamicin during enterococcal pyelonephritis.

Authors:  P Auclair; C Lessard; M G Bergeron
Journal:  Antimicrob Agents Chemother       Date:  1988-05       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.